News Feed Item

Collaboration Results, Litigation Update, Market Activity, Earnings Release, and Clinical Trial Results - Research Reports on Aetna, Allergan, Valeant, Perrigo and Baxter

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 1, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Aetna Inc. (NYSE: AET), Allergan Inc. (AGN: AGN), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Perrigo Company Public Limited Company (NYSE: PRGO) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6107-100free.

Aetna Inc. Research Reports
On August 27, 2014, Aetna Inc. (Aetna) announced that its accountable care collaboration with Banner Health Network (BHN) has resulted in c.$5 million of shared savings on Aetna Whole Health fully-insured commercial membership in 2013 and also witnessed a 5% decline in average medical cost on the members. According to the Company, the collaboration also resulted in improved cancer screening rates, blood sugar management in diabetic members and reduced avoidable hospital admissions. Chuck Lehn, BHN's CEO said, "Aetna and BHN have a collaborative relationship that is to the benefit of our members and employers. These results are rewarding because they validate our model- it is possible to deliver quality care at more affordable prices." The full research reports on Aetna are available to download free of charge at:


Allergan Inc. Research Reports
On August 26, 2014, Allergan Inc. (Allergan) announced that it has requested the United States District Court for the Central District of California to set an expedited schedule for discovery and a motion for a preliminary injunction against Valeant Pharmaceuticals (Valeant), Pershing Square Capital Management, L.P. (Pershing Square), and its principal, William A. Ackman for violating federal securities laws. The Company also announced a Special Meeting of Stockholders to be held on December 18, 2014 in which shareholders of record at the close of business on October 27, 2014 will be entitled to vote. According to the Company, in its preliminary injunction movement, it will seek an order barring Valeant, Pershing Square, Mr. Ackman, and individuals affiliated with them from exercising any rights or benefits associated with Allergan shares that might have been acquired illegitimately and would prevent Valeant, Pershing Square, and Mr. Ackman from voting their shares in any special meeting. The full research reports on Allergan are available to download free of charge at:


Valeant Pharmaceuticals International, Inc. Research Reports
On August 27, 2014, Valeant Pharmaceuticals International, Inc.'s (Valeant) stock declined 0.33% to end the trading session at $116.71. During the day, the stock opened at $118.25 and fluctuated within the range of $115.60 and $118.39, with a total of 1.35 million shares changing hands. Valeant's stock underperformed Dow Jones Industrial Average index which ended the session 0.09% higher. The full research reports on Valeant are available to download free of charge at:


Perrigo Company Public Limited Company Research Reports
On August 14, 2014, Perrigo Company Public Limited Company (Perrigo) reported its Q4 FY 2014 and FY 2014 financial results (period ended June 28, 2014). The net sales for the quarter came in at $1.1 billion, up 18.3% YoY, mainly due to the new product sales of $65 million, $112 million attributable to the acquisition of Elan Corporation plc, and product acquisitions from Fera Pharmaceuticals, LLC and Aspen Global Inc. Net sales for FY 2014 came in at $4.1 billion, up 14.7% YoY, primarily led by $290 million in sales attributable to the Elan, Rosemont Pharmaceuticals, Ltd., Sergeant's Pet Care Products, Inc., Fera, Velcera Inc. and Aspen acquisitions and new product sales of $231 million. The net income for FY 2014 declined 53.5% YoY to $205.3 million, while net income for Q4 FY 2014 came in at $131.7 million, up 11.1% YoY. The Company expects diluted EPS for FY 2015 to range from $4.05 to $4.35 and net income to range from $546.1 million to $586.6 million. The full research reports on Perrigo are available to download free of charge at:


Baxter International Inc. Research Reports
On August 21, 2014, Baxter International Inc. (Baxter) announced encouraging results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)]. Top-line results from the study demonstrated that BAX 855 achieved its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. According to the Company, patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median annualized bleed rates versus those in the on-demand arm. Baxter added that it anticipates submitting a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before 2014 year-end and will present additional data in the coming months. The full research reports on Baxter are available to download free of charge at:


About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DXWorldEXPO LLC announced today that "Miami Blockchain Event by FinTechEXPO" has announced that its Call for Papers is now open. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Financial enterprises in New York City, London, Singapore, and other world financial capitals are embracing a new generation of smart, automated FinTech that eliminates many cumbersome, slow, and expe...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: implemen...
DXWorldEXPO LLC announced today that ICOHOLDER named "Media Sponsor" of Miami Blockchain Event by FinTechEXPO. ICOHOLDER give you detailed information and help the community to invest in the trusty projects. Miami Blockchain Event by FinTechEXPO has opened its Call for Papers. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Miami Blockchain Event by FinTechEXPO also offers s...
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
@DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises - and delivering real results.
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
"We started a Master of Science in business analytics - that's the hot topic. We serve the business community around San Francisco so we educate the working professionals and this is where they all want to be," explained Judy Lee, Associate Professor and Department Chair at Golden Gate University, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
DXWorldEXPO LLC announced today that Dez Blanchfield joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Dez is a strategic leader in business and digital transformation with 25 years of experience in the IT and telecommunications industries developing strategies and implementing business initiatives. He has a breadth of expertise spanning technologies such as cloud computing, big data and analytics, cognitive computing, m...
Digital Transformation and Disruption, Amazon Style - What You Can Learn. Chris Kocher is a co-founder of Grey Heron, a management and strategic marketing consulting firm. He has 25+ years in both strategic and hands-on operating experience helping executives and investors build revenues and shareholder value. He has consulted with over 130 companies on innovating with new business models, product strategies and monetization. Chris has held management positions at HP and Symantec in addition to ...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...